Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug symbols : FNCTF save search
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
Published: 2024-01-05 (Crawled : 22:00) - biospace.com/
NTRB | $3.56 -8.76% 3.4K
|
Manufacturing
|
| O: 8.3%
H: 7.23%
C: 7.23%
drug commercial agreement
Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
LEXX | $2.18 -2.68% -2.75% 98K
|
Health Technology
|
| O: -1.54%
H: 9.38%
C: 8.59%
drug technology
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study
Published: 2023-11-27 (Crawled : 20:00) - biospace.com/
LEXX | $2.18 -2.68% -2.75% 98K
|
Health Technology
|
| O: 2.29%
H: 35.07%
C: 21.64%
drug technology pilot study
World Precision Instruments Expands EVOM™ Auto with Both 24 and 96 Multiwell Plate Capability, Combining Transepithelial Electrical Resistance (TEER) Measurements with a High Throughput Format for Drug Discovery
Published: 2023-10-23 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
drug world
Antibody Drug Conjugate - Competitive Landscape 2023 Study: Featuring Coverage on 180+ Companies and 300+ Drugs
Published: 2023-06-30 (Crawled : 18:00) - prnewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
drug companies antibody
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
Published: 2023-04-13 (Crawled : 12:20) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 0.0%
H: 2.32%
C: 0.6%
lp-284 pharma drug patent candidate
Cerner Enviza Collaborates with FDA to Develop Innovative AI Tools for Drug Safety and Real-World Evidence Studies
Published: 2023-04-10 (Crawled : 13:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 1.22%
H: 0.0%
C: -0.4%
ORCL | News | $115.34 0.22% -0.3% 5.2M
|
Technology Services
|
| O: -1.29%
H: 0.45%
C: -0.97%
fda drug tools
Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development
Published: 2023-04-04 (Crawled : 11:00) - nutriband.com
NTRB | $3.56 -8.76% 3.4K
|
Manufacturing
|
| O: 1.97%
H: 4.84%
C: 1.61%
drug commercial
Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway
Published: 2023-03-15 (Crawled : 12:20) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
drug therapeutics cancer
United States Honey Market Estimates & Forecasts, 2017-2021 & 2022-2030 - Rising Demand for Natural Sweeteners and Increasing Utilization in Drug Manufacturing
Published: 2023-02-24 (Crawled : 01:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
drug natural market
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 0.68%
H: 0.0%
C: 0.0%
FENC M | $10.5 -3.05% -3.14% 100K
|
Health Technology
|
| O: -0.21%
H: 8.3%
C: 6.49%
pedmark fda pharmaceuticals drug
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
Published: 2023-01-23 (Crawled : 13:20) - globenewswire.com
CPRX | News | $15.12 2.65% 2.58% 940K
|
Health Technology
|
| O: -11.92%
H: 0.49%
C: -19.43%
firdapse pharmaceuticals drug application
City of Hope-led trial leads to U.S. Food and Drug Administration's approval of a first of its kind bispecific antibody
Published: 2023-01-05 (Crawled : 19:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
drug antibody trial approval food
Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award for Drug Delivery Technology
Published: 2022-11-15 (Crawled : 21:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.34%
H: 0.61%
C: -0.16%
award sciences drug life technology innovation platform
Nutriband with Kindeva Drug Delivery demonstrate enhanced abuse-deterrent characteristics for Aversa™ Fentanyl
Published: 2022-10-04 (Crawled : 11:00) - nutriband.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -4.53%
H: 0.0%
C: 0.0%
NTRB | $3.56 -8.76% 3.4K
|
Manufacturing
|
| O: -1.06%
H: 11.8%
C: 10.99%
drug
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
Published: 2022-08-16 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.71%
H: 1.04%
C: 0.7%
lynparza fda drug application grants review cancer submission prostate cancer
Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance
Published: 2022-08-03 (Crawled : 17:00) - biospace.com/
OCUP | News | $1.52 -1.3% -1.32% 90K
|
Health Technology
|
| O: 1.65%
H: 6.49%
C: 2.43%
nyxol drug patent candidate
Avadel Sues HHS and FDA for Not Approving Narcolepsy Drug
Published: 2022-07-25 (Crawled : 17:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
fda drug narcolepsy
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication
Published: 2022-06-29 (Crawled : 14:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 2.72%
H: 1.23%
C: 1.23%
OCUP | News | $1.52 -1.3% -1.32% 90K
|
Health Technology
|
| O: 2.04%
H: 0.19%
C: -6.0%
apx3330 drug patent candidate granted publication
DelNova to Advance ReViVox™, A Groundbreaking Rescue Drug to Reverse Botulinum Toxin Neuromodulator Complications
Published: 2022-04-01 (Crawled : 18:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
drug
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.